Filing Flows › Comparisons › AVBP vs EQ
ArriVent BioPharma vs Equillium: AVBP and EQ compared
ArriVent BioPharma is the larger company: $5.0M of revenue in its latest quarter (Q3 2026) against $4.4M for Equillium (Q4 2024). Equillium is more profitable, with an operating margin of -107.0% against -867.5%.
Where the money goes: AVBP and EQ
ArriVent BioPharma (AVBP) · Q3 2026
ArriVent BioPharma, Q3 2026: revenue $5.0M, operating margin -867.5%, net loss $40.3M, operating cash flow −$40.7M. The chart follows the revenue to costs, profit and cash.
Equillium (EQ) · Q4 2024
Equillium, Q4 2024: revenue $4.4M (-52% year over year), operating margin -107.0%, net loss $5.8M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.
| ArriVent BioPharma (AVBP) | Equillium (EQ) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q4 2024 |
| Revenue | $5.0M | $4.4M |
| Revenue growth, Y/Y | — | -52% |
| Operating margin | -867.5% | -107.0% |
| Net earnings | −$40.3M | −$5.8M |
| Net margin | -806.3% | -131.9% |
| Operating cash flow | −$40.7M | −$3.3M |
Questions
Which is bigger, ArriVent BioPharma or Equillium?
ArriVent BioPharma is the larger company: $5.0M of revenue in its latest quarter (Q3 2026) against $4.4M for Equillium (Q4 2024).
Is ArriVent BioPharma or Equillium growing faster?
Equillium is more profitable, with an operating margin of -107.0% against -867.5%.
More: ArriVent BioPharma earnings · how ArriVent BioPharma makes money · Equillium earnings · how Equillium makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-K filed Mar 27, 2025). Fiscal quarters can end on different dates. Not investment advice.